The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationThe World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Self-citationCools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Self-citationPhiladelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Editorial: Some Speculations on the Myeloproliferative Syndromes
DAMESHEK, W. (1951) · Blood · doi:10.1182/blood.v6.4.372.372 · Cited by 1,082
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Self-citationWidespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Polycythemia Vera: Stem-Cell and Probable Clonal Origin of the Disease
Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F., & Steinmann, L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197610212951702 · Cited by 640
Diagnosis and classification of the polycythemias.
Berlin, N. I. (1975) · PubMed · Cited by 541
Clonal origin of chronic myelocytic leukemia in man.
Fialkow, P. J., Gartler, S. M., & Yoshida, A. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.4.1468 · Cited by 525
Jacobson, R., Salo, A., & Fialkow, P. (1978) · Blood · doi:10.1182/blood.v51.2.189.189 · Cited by 493
Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., Gilliland, D. G., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2005-03-1183 · Cited by 466
Self-citationShannon, K. M., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P., & McCormick, F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 444
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 432
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
Fialkow, P., Faguet, G., Jacobson, R., Vaidya, K., & Murphy, S. (1981) · Blood · doi:10.1182/blood.v58.5.916.916 · Cited by 386
Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J. T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H. M., & Issa, J.-P. J. (2005) · Blood · doi:10.1182/blood-2005-05-1800 · Cited by 369
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J., & Fletcher, J. A. (1998) · Nature Genetics · doi:10.1038/ng0198-84 · Cited by 323
Pardanani, A., Brockman, S. R., Paternoster, S. F., Flynn, H. C., Ketterling, R. P., Lasho, T. L., Ho, C.-L., Li, C.-Y., Dewald, G. W., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-03-0787 · Cited by 309
Self-citationWolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Self-citationPardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationEosinophilia: secondary, clonal and idiopathic
Tefferi, A., Patnaik, M. M., & Pardanani, A. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06038.x · Cited by 298
Self-citationPardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Self-citation松山, 智. (2005) · Mebio oncology · Cited by 242
Levine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D. G., & Busque, L. (2006) · Blood · doi:10.1182/blood-2005-09-3900 · Cited by 241
Lippert, E., Boissinot, M., Kralovics, R., Girodon, F., Dobo, I., Praloran, V., Boiret-Dupré, N., Skoda, R. C., & Hermouet, S. (2006) · Blood · doi:10.1182/blood-2006-01-013540 · Cited by 234
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V, Longo, G., Bosi, A., & Vannucchi, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403902 · Cited by 229
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Campbell, P. J. (2006) · Blood · doi:10.1182/blood-2005-08-3395 · Cited by 224
Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E. D., Theil, K. S., Sekeres, M. A., & Maciejewski, J. P. (2006) · Blood · doi:10.1182/blood-2006-02-005751 · Cited by 209
Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05776.x · Cited by 207
Self-citationThe haematocrit and platelet target in polycythemia vera
Di Nisio, M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06430.x · Cited by 183
Yavuz, A. S., Lipsky, P. E., Yavuz, S., Metcalfe, D. D., & Akin, C. (2002) · Blood · doi:10.1182/blood-2002-01-0203 · Cited by 169
Akin, C., Kirshenbaum, A. S., Semere, T., Worobec, A. S., Scott, L. M., & Metcalfe, D. D. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(99)00145-9 · Cited by 167
Oncogenes in Myeloproliferative Disorders
Tefferi, A., & Gilliland, D. G. (2007) · Cell Cycle · doi:10.4161/cc.6.5.3919 · Cited by 162
Self-citationClinical correlates of JAK2V617F allele burden in essential thrombocythemia
Kittur, J., Knudson, R. A., Lasho, T. L., Finke, C. M., Gangat, N., Wolanskyj, A. P., Li, C., Wu, W., Ketterling, R. P., Pardanani, A. D., et al. (2007) · Cancer · doi:10.1002/cncr.22663 · Cited by 157
Self-citationDiagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
Mossuz, P., Girodon, F., Donnard, M., Latger‐Cannard, V., Dobo, I., Boiret, N., Lecron, J., Binquet, C., Barro, C. D., Hermouet, S., et al. (2004) · PubMed · Cited by 156
Steensma, D. P., McClure, R. F., Karp, J. E., Tefferi, A., Lasho, T. L., Powell, H. L., Dewald, G., & Kaufmann, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404206 · Cited by 148
Self-citationDetection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couédic, J. L., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404069 · Cited by 144
Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia
Messinezy, M., Westwood, N., El‐Hemaidi, I., Marsden, J. T., Sherwood, R. A., & Pearson, T. C. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03386.x · Cited by 127
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors
Sidon, P., Housni, H. E., Dessars, B., & Heimann, P. (2006) · Leukemia · doi:10.1038/sj.leu.2404292 · Cited by 124
Lengfelder, E., Hochhaus, A., Kronawitter, U., Höche, D., Queißer, W., Jahn‐Eder, M., Burkhardt, R., Reiter, A., Ansari, H., & Hehlmann, R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00529.x · Cited by 122
Tefferi, A., & Gilliland, D. G. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.7.947 · Cited by 119
Self-citationClonality of Isolated Eosinophils in the Hypereosinophilic Syndrome
Chang, H.-W., Leong, K.-H., Koh, D.-R., & Lee, S. (1999) · Blood · doi:10.1182/blood.v93.5.1651 · Cited by 96
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
Inapparent Polycythemia Vera: An Unrecognized Diagnosis
Lamy, T., Devillers, A., Bernard, M., Moisan, A., Grulois, I., Drénou, B., Amiot, L., Fauchet, R., & Prisé, P. Y. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00351-8 · Cited by 86
Robyn, J. A., Lemery, S. J., McCoy, J. P., Kubofcik, J., Kim, Y., Pack, S., Nutman, T. B., Dunbar, C. E., & Klion, A. D. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05863.x · Cited by 79
Chronic myeloproliferative disorders: a tyrosine kinase tale
Keersmaecker, K. D., & Cools, J. (2006) · Leukemia · doi:10.1038/sj.leu.2404064 · Cited by 75
Boissinot, M., Lippert, É., Girodon, F., Dobo, I., Fouassier, M., Masliah, C., Praloran, V., & Hermouet, S. (2006) · Blood · doi:10.1182/blood-2006-05-021527 · Cited by 69
A Comparative Review of Classification Systems in Myelodysplastic Syndromes (MDS)
Bennett, J. M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.06.021 · Cited by 68
Biologic response modifiers in non-Hodgkin's lymphomas.
Gilewski, T. A., & Richards, J. M. (1990) · PubMed · Cited by 65
Heller, P. G., Lev, P. R., Salim, J. P., Kornblihtt, L. I., Goette, N. P., Chazarreta, C. D., Glembotsky, A. C., Vassallu, P. S., Marta, R. F., & Molinas, F. C. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00688.x · Cited by 60
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7
Fröhling, S., Lipka, D. B., Käyser, S., Scholl, C., Schlenk, R. F., Döhner, H., Gilliland, D. G., Levine, R. L., & Döhner, K. (2006) · Blood · doi:10.1182/blood-2005-09-3644 · Cited by 58
Evidence of clonality in chronic neutrophilic leukaemia
Böhm, J., Kock, S., Schaefer, H. E., & Fisch, P. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.4.292 · Cited by 58
Tefferi, A., Lasho, T. L., Brockman, S. R., Elliott, M. A., Dispenzieri, A. A., & Pardanani, A. D. (2004) · PubMed · Cited by 58
Self-citationSystemic mastocytosis: current concepts and treatment advances.
Tefferi, A., & Pardanani, A. D. (2004) · PubMed · Cited by 45
Self-citationTaylor, M. L., Sehgal, D., Raffeld, M. A., Obiakor, H., Akin, C., Mage, R. G., & Metcalfe, D. D. (2004) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60529-6 · Cited by 45
Pearson, T. C. (1991) · Blood Reviews · doi:10.1016/0268-960x(91)90010-a · Cited by 44
Tefferi, A., & Pardanani, A. D. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.5.599 · Cited by 36
Self-citationPardanani, A. D., Lasho, T. L., Schwager, S. M., Finke, C. M., Hussein, K., Pruthi, R. K., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404710 · Cited by 33
Self-citationScreening of JAK2 V617F mutation in multiple myeloma
Fiorini, A., Farina, G., Reddiconto, G., Palladino, M., Rossi, E., Zà, T., Laurenti, L., Giammarco, S., Chiusolo, P., Leone, G. G. M., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404332 · Cited by 22
Kremer, M., Horn, T. D., Dechow, T. N., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404231 · Cited by 14
Cited by
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Valent, P., Klion, A. D., Horny, H.-P., Roufosse, F., Gotlib, J., Weller, P. F., Hellmann, A., Metzgeroth, G., Leiferman, K. M., Arock, M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.019 · Cited by 767
Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 533
Self-citation
Metadata
- Authors
- Tefferi, A., & Vardiman, J. W.
- Venue
- Leukemia
- Published
- 2007-09-20
- Volume
- 22
- Issue
- 1
- Pages
- 14-22
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1985177017
- Cited by
- 1,002
- References
- 73
- FWCI
- 35.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.